Browse Category

NASDAQ:SPRE News 4 January 2026

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

NEW YORK, January 3, 2026, 20:15 ET — Market closed Spyre Therapeutics, Inc. shares fell 6.6% on Friday to $30.58, finishing the first U.S. trading day of 2026 near the lower end of the session’s $30.11-$33.31 range. The stock remains below its 52-week high of $34.49 after trading about 889,000 shares, while biotech benchmarks were little changed. The slide stands…

Stock Market Today

  • Should Investors Buy Amazon Stock Ahead of Q4 Earnings?
    February 5, 2026, 10:58 AM EST. Amazon's upcoming Q4 earnings report is drawing investor attention amid cautious market sentiment. Market watchers are weighing Amazon.com's growth prospects in retail and cloud computing against challenges like supply chain disruptions and inflation pressures. The report could set the tone for how the stock performs in the near term, given its substantial role in the tech and consumer sectors. Investors face a crucial decision: to buy ahead of the release, betting on strong results, or wait for clearer signals from the company's performance. Analyst forecasts vary, reflecting uncertainty over consumer demand trends and Amazon Web Services' growth. The Q4 report offers a key opportunity to gauge Amazon's resilience in a complex economic landscape.
Go toTop